Anticoagulant effects of low-molecular-weight heparin following thrombolytic therapy in acute myocardial infarction: A dose-finding study

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue 5, 1996, Pages 247-257

  Strandberg, Lars Erik ^a   Kahan, Thomas ^a   Lundin, Peter ^a   Svensson, Jan ^b   Erhardt, Leif ^c  

^a Divisions oflntcrnal Medicine   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Anti factor Xa; Dalteparin; Hemostasis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTICOAGULANTS; ANTITHROMBIN III; DALTEPARIN; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FEMALE; FIBRINOGEN; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PARTIAL THROMBOPLASTIN TIME; REGRESSION ANALYSIS; THROMBOLYTIC THERAPY;

EID: 0029777559     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217215     Document Type: Article

References (23)

1. ISIS-2 Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;vol ii:349-360.
2. The SCATI (Studio sulla Calcipari-na nell’Angina e nella Trombosi ventricolare nell’Infarto) Group: Randomized controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 1989; vol ii: 182-186.
3. Hsia J, Klciman NS, Aguirre F, Chaitman BR. Roberts R, Ross AM, for the Heparin Aspirin Reperfu sion Trial (HART) Investigators: Heparin induced prolongation of partial thromboplastin time after thrombolysis: Relation to coronary artery patency. J Am Coll Cardiol 1992;20:31-35.
4. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
5. Turpie AGG, Robinson JG, Doyle DJ, Mulji AS, Mishkcl GJ, Sealey BJ, Cairns JA, Skingley L, Hirsh J, Gent M: Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 1989;320: 352-357.
6. Davies MJ, Thomas AC: Plaque Assuring: The cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985;53:363-373.
7. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303: 897-902.
8. Fibrinolytic Therapy Trialists (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of mortality and major morbidity results from all randomised trials of more than 1.000 patients. Lancet 1994,343: 311-322.
9. GISS1-Gruppo Italiano per lo Studio Della’Streptochinasi Nell’Infar-to Miocardico: Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;vol i:397-401.
10. Bates ER, Topol EJ: Thrombolytic mortality trials; in Bates E (cd): Thrombolysis and Adjunctive Therapy for Acute Myocardial Infarction. New York, Dekker, 1993, pp 63-90.
11. Abendschein DR: Relationships between suppression of coagulation and prevention of reocclusion; in Sobel BE, Collen D (ed): Coronary Thrombolysis in Perspective. Principles Underlying Conjunctive and Adjunctive Therapy. New York, Dekker, 1993, pp 123-142.
12. Prins MEL Hirsh J: Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1991;67: 3A-11A.
13. Wcitz JI, Hirsh J: Antithrombins: Their potential as antithrombotic agents. Annu Rev Med 1992;43:9-16.
14. Gruppo Italiano per lo Studio della Sopravivienza nell'Infarto miocardico: GISSI-2: A factorial randomised trial of altcplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990:336.65-71.
15. ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-770.
16. Holm HA. Ly B. Handeland GF, Abildgaard U, Arnesen K.E, Gott-schalk P, Hoeg V, Aandahl M, Haugen K, Laerum F, Schccl B, Sortland O, Vinle B: Subcutaneous heparin treatment of deep venous thrombosis: A comparison of un-fractionatcd and low molecular weight heparin. Haemostasis 1986; 16(suppl 2):30-37.
17. Lockncr D. Bratt G, Tomebohm W, Aberg W, Granqvist S: Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis. Haemostasis 1986;16(suppl 2): 25-29.
18. Arnesen KE, Handeland GF, Abildgaard U, Gottschalk P, Stene-Larsen G, Nilsen DWT: What is the optimal dosage of LMW heparin in the subcutaneous treatment of deep venous thrombosis? (abstract 194). Thromb Haemost 11th Int Congr. Brussels, 1987.
19. Bratt G: Subcutaneous Fragmin twice daily in the treatment of DVT. ICTH Satellite Symposium, July 1987. Thromb Haemost 11th Int Congr, Brussels, 1987.
20. Nesvold A, Kontny F, Abildgaard U, Dale J: Safety of high doses of low molecular weight heparin (Fragmin) in acute myocardial infarction. A dose-finding study. Thromb Res 1991;64:579-587.
21. Ludlam CA, Bennett B, Fox KAA. Lowe GDO, Reid AW: Guidelines for the use of thrombolytic therapy. Blood Coagul Fibrinolysis 1995;6: 273-285.
22. Harenbcrg J, Hcenc DL: Pharmacology and special clinical applications of low-molecular-weight hepa-rins. Am J Hcmatol 1988,29:233-240.
23. Marciniak E, Gockerman JP: Heparin-induced decrease in circulating antithrombin-lll. Lancet 1977;vol ii: 581-585.